31,249 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Value Star Asset Management Hong Kong Ltd

Value Star Asset Management Hong Kong Ltd purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 31,249 shares of the company's stock, valued at approximately $3,107,000. Moderna accounts for 1.1% of Value Star Asset Management Hong Kong Ltd's investment portfolio, making the stock its 12th largest holding.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Moderna by 0.7% during the third quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company's stock worth $2,856,841,000 after buying an additional 196,012 shares during the last quarter. Wellington Management Group LLP raised its stake in Moderna by 9.3% during the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company's stock worth $579,572,000 after buying an additional 476,201 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company's stock worth $400,367,000 after buying an additional 1,690,341 shares during the last quarter. Invesco Ltd. raised its stake in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock worth $322,887,000 after buying an additional 517,683 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Moderna by 1.9% during the third quarter. Northern Trust Corp now owns 2,971,056 shares of the company's stock worth $306,880,000 after buying an additional 55,177 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the sale, the director now owns 2,101,931 shares of the company's stock, valued at $229,236,594.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the completion of the transaction, the director now directly owns 2,101,931 shares of the company's stock, valued at approximately $229,236,594.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 2,388 shares of the firm's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares of the company's stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders have sold a total of 124,954 shares of company stock worth $13,158,776 over the last three months. 15.20% of the stock is currently owned by insiders.

Moderna Stock Performance

MRNA traded up $1.15 during midday trading on Wednesday, reaching $111.46. The company had a trading volume of 3,837,007 shares, compared to its average volume of 4,047,055. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The stock has a market cap of $42.68 billion, a PE ratio of -8.98 and a beta of 1.62. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $142.79. The business has a 50-day moving average price of $103.95 and a two-hundred day moving average price of $93.92.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company's quarterly revenue was down 44.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.61 earnings per share. On average, sell-side analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MRNA. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Thursday, April 11th. Canaccord Genuity Group lifted their price target on shares of Moderna from $82.00 to $91.00 and gave the company a "hold" rating in a research note on Friday, February 23rd. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $125.00 price target on shares of Moderna in a research note on Thursday, March 28th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. Finally, HSBC reaffirmed a "reduce" rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.